received a $16.2 million contract from the National Institutes of Health's allergy and infectious disease group to develop an HIV vaccine.
Through the contract, Crucell will be collaborating with
Charles River Laboratories
and the Beth Israel Deaconess Medical Center at Harvard Medical School. The program will also be supported by the National Institute of Allergy and Infectious Diseases Vaccine Research Center.
"We are very grateful to the NIAID for their support and ongoing endorsement of our technology in the field of HIV vaccine development," said Crucell's chief scientific officer, Dr. Jaap Goudsmit, in a press release Monday. "Multiple high-level vaccine initiatives are essential if we are to be successful in delivering the safe, effective and accessible HIV vaccine that the world needs so urgently."
Shares of Crucell were up 2.3% to $23.70.